Using regulatory CD8 T cells to calm autoimmune attacks in MS
Immunotherapeutic Regulatory CD8 T cells in Autoimmune Demyelinating Disease
['FUNDING_OTHER'] · IOWA CITY VA MEDICAL CENTER · NIH-11138542
This work explores whether a special type of immune cell (regulatory CD8 T cells) can be used to reduce the immune attack that damages nerves in people with multiple sclerosis.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | IOWA CITY VA MEDICAL CENTER (nih funded) |
| Locations | 1 site (IOWA CITY, UNITED STATES) |
| Trial ID | NIH-11138542 on ClinicalTrials.gov |
What this research studies
Researchers are studying a type of CD8 immune cell that appears to suppress the damaging immune response in multiple sclerosis. They use an established animal model of MS to learn how these cells work, including the signals they use, how they travel to the brain and spinal cord, and how they stop inflammation. The team aims to identify a strong, boostable subset of these regulatory CD8 cells and test a vaccination approach to enhance their protective function. Results could point the way toward therapies that harness a person’s own immune cells to limit relapses and nerve damage.
Who could benefit from this research
Good fit: People with a diagnosis of multiple sclerosis—especially those with active or relapsing disease—would be the most likely candidates for future therapies based on this work.
Not a fit: Patients with non‑autoimmune neurological conditions or those with long‑standing progressive MS without active inflammation may be less likely to benefit from immune‑based approaches.
Why it matters
Potential benefit: If successful, this approach could lead to new immunotherapies that reduce central nervous system inflammation and slow or prevent MS relapses and progression.
How similar studies have performed: Most past MS research targeted CD4 T cells, so using regulatory CD8 T cells is a relatively novel approach, though some animal and early human data suggest CD8 cells can suppress autoimmune damage.
Where this research is happening
IOWA CITY, UNITED STATES
- IOWA CITY VA MEDICAL CENTER — IOWA CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KARANDIKAR, NITIN J — IOWA CITY VA MEDICAL CENTER
- Study coordinator: KARANDIKAR, NITIN J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.